Robert J. Lee
Pharmaceutics and Pharmaceutical Chemistry
542 Parks Hall


  • Targeted drug delivery systems based on nanoparticles
  • Improving nanoparticle composition for clinical applications
  • Developing miR-targeting lipid nanoparticles
  • Targeted chemotherapeutic drug formulations and bioconjugates

Professional Interests

Dr. Lee's lab is focused on targeted drug delivery systems based on nanoparticles. Nanoparticles can serve as carriers of therapeutic agents, including nucleic acids such as siRNA, miRNA and anti-miRs, and facilitate their therapeutic delivery. The lab's effort is focused on improving nanoparticle composition based on rational design and directed at clinical applications. Ongoing projects include developing miR-targeting lipid nanoparticles and targeted chemotherapeutic drug formulations and bioconjugates for therapy of solid tumors, leukemias, diabetic wounds, and other diseases.


  • Postdoctoral, 1995, University of Pittsburgh
  • PhD, 1994, Purdue University, Biological Sciences


  • Named “2015 Ohio State University Innovator of the Year”. This award recognizes outstanding contribution to developing innovative technologies that lead to patent applications, licensing agreements, and commercialization.
  • 2011 AAPS Innovation Biotechnology Awards for the abstract Zhou and Lee “Cellular pharmacokinetics (PK) and target gene knockdown of surfactant‐ and lipid‐based nanocarriers (NCs) of siRNA”
  • 2009 Selection to the NIH Nanotechnology Study Section as a chartered member
  • 2006 Highest Cited Original Research Award, Int. J. Pharm. for the article Wu, J., Liu, Q., and Lee, R.J. “A folate receptor-targeted liposomal formulation for paclitaxel” Int. J. Pharm. 316:148-153

Recent Publications